The Impact of COVID-19 on Access to Parkinson's Disease Medication.

Julia Ling-Yu CheongZhao Hang Keith GohConnie MarrasCaroline M TannerMeike KastenAlastair J Noycenull null

Published in: Movement disorders : official journal of the Movement Disorder Society (2020)

Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
newly diagnosed
ejection fraction
healthcare
chronic kidney disease
peritoneal dialysis
prognostic factors
adverse drug
emergency department
randomized controlled trial